Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

20,711 total articles

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

MBX Biosciences has dosed the first patient in its pivotal Phase 3 oPTimize trial evaluating once-weekly canvuparatide for chronic hypoparathyroidism treatment. Building on positive Phase 2 results, the global trial aims to demonstrate the drug's efficacy and safety as a potential best-in-class parathyroid hormone replacement therapy. This mileston…

ROC Secures Landmark Five-Year $5.1 Million Federal ABIS Contract

ROC Secures Landmark Five-Year $5.1 Million Federal ABIS Contract

Rank One Computing Corporation (ROC) has won a significant five-year contract valued at $5.1 million to supply its multimodal automated biometric identification system (ABIS) to a major federal national security program. This contract marks a strategic breakthrough for ROC in the U.S. federal biometrics market, establishing a foundational customer …

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Verrica Pharmaceuticals has announced the completion of patient enrollment in the first pivotal Phase 3 trial (COVE-2) evaluating YCANTH® (VP-102) for common warts treatment, with topline data expected in the first quarter of 2027. The company is on track with its global Phase 3 program, which also includes a second trial (COVE-3) over 50% enrolled…

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri Inc., a biotechnology company operating in the human health and FoodTech sectors, has priced a $3.3 million registered direct offering, including the sale of 2,228,940 common shares to a single healthcare-focused institutional investor at $1.50 per share. Concurrently, the company will issue unregistered warrants exercisable at $1.65 per shar…

Entera to Participate in Upcoming Fall Investor Conferences

Entera to Participate in Upcoming Fall Investor Conferences

Entera Bio Ltd., a clinical stage biotechnology company specializing in oral peptide therapies, announced its CEO Miranda Toledano will participate in several prominent healthcare investor conferences throughout fall 2026. The company highlighted its proprietary N-Tab technology platform and diverse pipeline including its leading osteoporosis candi…

ChronoScale Announces AI Infrastructure Partnership with Microsoft for 50 MW AI Compute Deployment in North America

ChronoScale Announces AI Infrastructure Partnership with Microsoft for 50 MW AI Compute Deployment in North America

ChronoScale Corporation announced a partnership with Microsoft to deploy a 50-megawatt AI compute infrastructure in North America. The deployment will utilize NVIDIA GB300 NVL72 systems coupled with advanced liquid-cooling technology to support high-density AI workloads. This full-stack infrastructure is designed to meet the power, cooling, network…

Alvotech to present at upcoming investor conferences in September

Alvotech to present at upcoming investor conferences in September

Alvotech, a global biotechnology company specializing in biosimilar medicines, announced that its Founder and Chairman, Robert Wessman, and Chief Strategy Officer, Dr. Balaji V. Prasad, will participate in upcoming investor conferences hosted by Morgan Stanley and Deutsche Bank in September 2026. These events include a fireside chat and investor me…

Expion Energy Appoints Robert Winspear as Chief Financial Officer

Expion Energy Appoints Robert Winspear as Chief Financial Officer

Expion Energy, Inc., a Nasdaq-listed company known for its lithium battery technology, appointed Robert Winspear as Chief Financial Officer, signaling a strategic focus on entering the oil and gas sector alongside its established battery business. Winspear brings extensive capital markets and M&A experience, supporting the company's growth plans an…

Nasdaq Verafin Partners with Q6 Cyber, Bringing Unique Intelligence Together for Proactive Fraud Prevention to Support Financial Institutions

Nasdaq Verafin Partners with Q6 Cyber, Bringing Unique Intelligence Together for Proactive Fraud Prevention to Support Financial Institutions

Nasdaq Verafin announced a partnership with Q6 Cyber to integrate dark web fraud intelligence into its financial crime management platform. This alliance aims to provide financial institutions with early alerts on compromised accounts and payment methods, allowing proactive fraud prevention prior to fraudulent transactions. The combined data from Q…

Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany

Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany

Catheter Precision, Inc. announced key commercial milestones including its first purchase order through Cardinal Health, an extensive U.S. healthcare distributor, and the first order from Johns Hopkins Hospital for its LockeT suture retention device. Additionally, the company has placed its VIVO 3D Imaging System with a hospital in Germany, marking…

3D Systems Launches Partnership with Savannah River National Laboratory to Advance 3D Printing for Advanced Energy and National Security Applications

3D Systems Launches Partnership with Savannah River National Laboratory to Advance 3D Printing for Advanced Energy and National Security Applications

3D Systems announced a strategic partnership with Savannah River National Laboratory (SRNL) through a Cooperative Research and Development Agreement to advance additive manufacturing technologies targeting advanced energy generation, including nuclear energy, and national security applications. The collaboration will focus on developing advanced ma…

Veea and Telarus Sign Technology Services Distribution Agreement to Expand Access to Secure, Intelligent Connectivity Solutions

Veea and Telarus Sign Technology Services Distribution Agreement to Expand Access to Secure, Intelligent Connectivity Solutions

Veea Inc., a Nasdaq-listed leader in AI-driven edge infrastructure, has signed a Technology Services Distribution Agreement with Telarus, a prominent technology services distributor. This partnership aims to expand Veea's secure connectivity, edge computing, and AI-enabled technology solutions through Telarus's extensive network of technology advis…

Caliber Launches - Caliber Tokenization Services, New Entity Bringing Real-World Asset Tokenization to Family-Owned Real Estate Portfolios

Caliber Launches - Caliber Tokenization Services, New Entity Bringing Real-World Asset Tokenization to Family-Owned Real Estate Portfolios

Caliber, a Nasdaq-listed real estate-focused alternative asset manager, announced the launch of Caliber Tokenization Services (CTS), a new division providing full-service real-world asset tokenization to family offices with significant real estate holdings. Following initial successful tokenization of its own portfolio, Caliber aims to simplify own…

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals announced the publication of final Phase 1/1b clinical trial data for its investigational drug soquelitinib, demonstrating promising anti-tumor activity and durable responses in patients with refractory T cell lymphoma. The data, published in the journal Blood, support ongoing Phase 3 and Phase 2 trials for various indication…

Nexalin Technology Announces Reverse Stock Split

Nexalin Technology Announces Reverse Stock Split

Nexalin Technology, Inc. approved and is implementing a 1-for-30 reverse stock split of its common stock effective August 28, 2026, to maintain compliance with Nasdaq bid-price requirements. The stock will continue trading under ticker NXL on Nasdaq from August 31, 2026. The company designs neurostimulation medical devices targeting mental health d…

Aveanna to Participate in the Deutsche Bank 2026 Healthcare Summit

Aveanna to Participate in the Deutsche Bank 2026 Healthcare Summit

Aveanna Healthcare announced its participation in the Deutsche Bank 2026 Healthcare Summit, including a management fireside chat and investor meetings. The company provides extensive pediatric and adult healthcare services across 39 states, focusing on home health, hospice, rehabilitation, and case management services as cost-effective alternatives…

Ambow Education Holding Ltd. (NYSE American: AMBO) Introduces HybriU as a Digital Intelligent Infrastructure

Ambow Education Holding Ltd. (NYSE American: AMBO) Introduces HybriU as a Digital Intelligent Infrastructure

Ambow Education Holding Ltd. (NYSE American: AMBO) has formally introduced HybriU, a Digital Intelligent Infrastructure platform that integrates ten products across three layers — Spatial Experience, AI Intelligence, and Knowledge Intelligence — to unify physical spaces, AI tools, and institutional knowledge in educational and enterprise settings. …